查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018483

人工器官與仿生市場：依產品、技術、應用及最終用戶分類－2026-2032年全球市場預測

Artificial Organ & Bionics Market by Product, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人造器官和仿生學市場價值將達到 277.2 億美元，到 2026 年將成長到 301.9 億美元，到 2032 年將達到 521.1 億美元，複合年成長率為 9.43%。

主要市場統計數據
基準年 2025 277.2億美元
預計年份：2026年 301.9億美元
預測年份 2032 521.1億美元
複合年成長率 (%) 9.43%

人工器官和仿生學生態系統的簡要概述：重點關注臨床促進因素、技術進步、監管趨勢和策略意義。

人工器官和仿生學領域正從一系列小眾干預措施發展成為一個整合的生態系統，連結先進的生物材料、精密電子技術和系統級臨床照護。人口老化、慢性器官衰竭盛行率上升以及生物修復不切實際或無法實施的適應症範圍不斷擴大，推動了臨床需求的成長。同時，組織工程、生物混合系統和神經介面等領域的技術成熟，正將實驗室可行性轉化為臨床應用設備。這一轉變標誌著一個轉折點：曾經作為臨時過渡方案的解決方案，正日益被視為更持久甚至永久性的治療選擇。

從材料科學的突破到與醫療服務的整合，本書揭示了正在重塑人造器官和仿生學發展的關鍵轉折點。

人造器官和仿生學領域的格局正受到多重因素的共同影響而重塑，這些因素重新定義了相互競爭的優先事項，並創造了新的商業性轉折點。生物材料、積層製造和微型化技術的進步拓展了技術可行性的範圍，使得開發出能夠更真實地模擬生理功能並與生物組織更有效地相互作用的設備成為可能。同時，數據分析和遠端監測技術的進步使移植後護理更具預防性，使臨床醫生能夠及早發現異常情況，並制定個人化的干涉措施，從而改善長期治療效果。

評估美國在 2025 年實施的新關稅措施對供應鏈、臨床實踐准入、製造業經濟和創新途徑的連鎖影響。

美國2025年宣布的關稅措施，為人工器官和仿生領域的全球價值鏈增添了新的複雜性。關稅帶來的成本壓力影響原料、精密零件和成品子系統，並波及到下游環節，例如設備組裝、檢驗和分銷。依賴跨境採購關鍵零件的製造商被迫做出諸如供應商多元化、將生產遷回國內或進行策略性庫存等決策，以降低風險並維持生產的連續性。

透過應用產品技術和分析終端用戶人口統計數據，我們將發現微妙的需求促進因素、臨床接觸點和投資重點領域。

深入了解產品層面的細分對於提升策略清晰度和確定研發優先事項至關重要。產品線涵蓋人工心臟、人工腎臟、人工肝臟、仿生義肢和義肢，每個產品類型都有其獨特的臨床工作流程、監管路徑和製造複雜性。在人工心臟領域，全人工心臟系統和心室輔助裝置之間的差異凸顯了應用情境、植入複雜性和術後照護模式的差異。同樣，人工腎臟分為血液透析機和腹膜透析機，它們在患者自我管理要求和對基礎設施的依賴性方面有所不同。人工肝臟技術分為生物假體肝臟支持裝置和體外肝臟輔助裝置，兩者分別代表了不同的生物整合程度以及短期支持和持續支持的不同模式。仿生義肢的研發涵蓋足部、手部、下肢和上肢的解決方案，這些解決方案在感測器精度、驅動機制和訓練要求方面各不相同。義肢產品包括人工電子耳、深部腦部刺激器和視網膜植入，每一種都連接到特定的神經通路，它們的最佳化需要獨特的臨床專業知識。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略定位正在影響臨床引進和製造地。

對於尋求引入人工器官和仿生解決方案的開發商、製造商和醫療保健系統而言，區域環境對其戰略選擇有顯著影響。美洲地區擁有先進的臨床基礎設施、特定司法管轄區內成熟的報銷機制以及重視已證實臨床療效和商業性價值的集中資本市場，這些優勢構成了一個充滿活力的多元化環境。這種環境有利於早期採用先進的治療性介入，並促進夥伴關係關係的建立，從而擴大外科手術計畫的規模並收集上市後證據。歐洲、中東和非洲的監管和支付環境各不相同，部分地區尤其注重透過臨床網路進行集中採購和檢驗。這有助於推動協作部署策略和多中心證據的產生。該地區的醫療保健系統通常優先考慮與現有臨床工作流程的互通性，以及能夠作為部署中心的區域卓越中心。亞太地區則兼具特定市場的快速臨床部署、大規模生產能力、對本土創新日益成長的重視。儘管該地區各市場在監管嚴格程度和報銷方案設計方面存在差異，但總體而言，它們為可擴展的生產和成本最佳化的設備改進提供了巨大的機會。

競爭格局分析，重點在於主要相關人員。

人工器官和仿生學領域的競爭格局呈現出技術差異化、策略夥伴關係以及涵蓋臨床檢驗和生產的執行能力相結合的特徵。關鍵企業是那些將強大的工程平台與臨床專業知識相結合的公司，這些公司能夠加快轉化研究（從基礎研究到臨床應用的轉換）並提供可靠的長期支援。保護核心感測、驅動和生物整合技術的智慧財產權組合，以及在監管和大規模生產流程方面的專業知識，共同構成了永續的競爭優勢。同樣重要的是，企業需要製定一套包含培訓、服務網路和資料生態系統的上市策略，以確保設備在不同的醫療環境中都能提供一致的療效。

為產業領導者提供可操作的策略重點，以加速商業化、降低地緣政治風險並最佳化臨床和生產流程。

產業領導者必須採取果斷行動，以應對先進器官和仿生市場中交織的臨床、監管和商業挑戰。首先，他們必須優先考慮整合隨機試驗數據、真實世界績效指標和遠端監測洞察的證據策略，從而為支付方和醫療服務提供者建立引人注目的長期價值主張。同時，他們必須投資於模組化產品架構，以方便組件更換和現場組裝，從而降低關稅衝擊和零件短缺的風險，同時保持臨床功能。透過儘早與監管機構合作、推行適應性核准流程以及設計上市後監測方案，他們可以在確保安全性和持續改進的同時，加快患者獲得治療。

嚴謹的混合方法研究設計，說明了分析中使用的主要訪談、次要檢驗、專家小組和三角測量方法。

本分析所依據的研究採用了混合方法，以確保對定性和定量數據進行可靠的檢驗。主要研究包括對臨床醫生、醫院採購經理、製造企業高管和監管專家進行結構化訪談，以獲取關於臨床工作流程、推廣障礙和供應鏈現狀的第一手觀點。除這些訪談外，還舉辦了專家圓桌會議，以促進跨學科討論並檢驗新出現的主題。次要研究則納入了公開的監管指南、同行評審的臨床文獻和企業資訊披露，以闡明主要研究的發現並明確技術發展路徑。

整合策略洞察，重點關注韌性優先事項、夥伴關係機會以及擴展先進人工器官和仿生解決方案的途徑。

這些分析表明，該領域正處於一個戰略十字路口，技術潛力與營運和商業複雜性在此交匯。生物材料、微型電子裝置和再生醫學技術的進步正在為更持久、更符合生理需求的解決方案鋪平道路。然而，要實現這一潛力，需要認真關注監管策略、生產規模化以及能夠引起支付方和醫療服務提供者共鳴的證據。地緣政治發展，包括關稅措施和供應鏈的不確定性，進一步凸顯了生產基地本地化和供應商多元化決策的迫切性。同時，特定地區的臨床實務和報銷框架要求採用因地制宜的商業化方法，而非一刀切的模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人工器官與仿生學市場：依產品分類

  • 人工心臟
    • 全人工心臟
    • 心室輔助裝置
  • 人工腎臟
    • 血液透析機
    • 腹膜透析機
  • 人工肝臟
    • 生物人工肝臟支持
    • 體外肝臟支援裝置
  • 仿生義肢
    • 腳
    • 手
    • 下肢
    • 上肢
  • 神經義肢
    • 人工電子耳
    • 深層腦部刺激器
    • 視網膜植入

第9章：人工器官與仿生市場：依技術分類

  • 生物人工器官
  • 機械器官
  • 組織工程器官

第10章：人工器官與仿生市場：依應用領域分類

  • 循環系統
  • 肝
  • 神經系統
  • 整形外科
  • 腎

第11章：人工器官與仿生市場：依最終使用者分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 專科診所

第12章：人工器官與仿生市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：人工器官與仿生市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人造器官與仿生市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：人工器官與仿生市場

第16章 中國：人造器官與仿生市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abiomed Inc
  • Asahi Kasei Medical Co Ltd
  • B Braun SE
  • Baxter International Inc
  • Berlin Heart GmbH
  • BiVACOR Pty Ltd
  • Boston Scientific Corporation
  • CARMAT SA
  • Cochlear Ltd
  • CYBERDYNE Inc
  • Edwards Lifesciences Corporation
  • Ekso Bionics Holdings Inc
  • Fresenius Medical Care AG
  • Getinge AB
  • Jarvik Heart Inc
  • LifeNet Health Inc
  • MED-EL
  • Medtronic plc
  • Open Bionics
  • Orthofix International NV
  • Ottobock
  • SynCardia Systems
  • Terumo Corporation
  • Zimmer Biomet Holdings Inc
  • Ossur
Product Code: MRR-A339DAEFA09B

The Artificial Organ & Bionics Market was valued at USD 27.72 billion in 2025 and is projected to grow to USD 30.19 billion in 2026, with a CAGR of 9.43%, reaching USD 52.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.72 billion
Estimated Year [2026] USD 30.19 billion
Forecast Year [2032] USD 52.11 billion
CAGR (%) 9.43%

A concise orientation to the artificial organ and bionics ecosystem highlighting clinical drivers technological progress regulatory momentum and strategic stakes

The artificial organ and bionics field is evolving from a collection of niche interventions into an integrated ecosystem linking advanced biomaterials, precision electronics, and systems-level clinical care. Clinical demand is being driven by aging populations, rising prevalence of chronic organ failure, and an expanding range of indications where biological repair is either impractical or unavailable. Concurrently, technological maturation in areas such as tissue engineering, biohybrid systems, and neural interfacing is converting laboratory feasibility into clinically actionable devices. This transition underscores a turning point: solutions that once served as temporary bridges are increasingly positioned as durable or permanent therapeutic options.

Regulatory pathways and reimbursement frameworks are adapting to accommodate these innovations, influencing both speed-to-market and post-market evidence generation. Investors and strategic partners are shifting their criteria to value long-term clinical durability, integration with digital health platforms, and the ability to demonstrate real-world patient benefit. The manufacturing landscape is also changing, with an emphasis on scalable processes, supply-chain resilience, and quality systems that meet complex biological and electronic integration requirements. Taken together, these forces are realigning priorities for developers, clinicians, and health systems, and set the stage for a decade defined by convergence between biological science and engineering practice.

Mapping the vital inflection points reshaping artificial organ and bionics development from material science breakthroughs to care-delivery integration

The landscape of artificial organs and bionics is being reshaped by several convergent shifts that redefine competing priorities and create new commercial inflection points. Advances in biomaterials, additive manufacturing, and miniaturized electronics have expanded what is technically feasible, enabling devices that better mimic physiological function and interface more effectively with native tissue. Parallel progress in data analytics and remote monitoring has made post-implant care more proactive, allowing clinicians to detect deviations early and tailor interventions in ways that improve long-term outcomes.

Institutional behaviors are also changing. Health systems increasingly value integrated therapeutic solutions that reduce hospital length of stay, lower complication rates, and deliver predictable downstream costs. This has important implications for how devices are designed, validated, and priced. In addition, strategic collaborations between medical device developers, surgical services, and biotech firms are accelerating translational pathways by combining clinical expertise with engineering capacity and commercial execution. These partnerships are shifting competitive dynamics away from isolated product development toward systems-based solutions.

Finally, regulatory frameworks are gradually evolving to reflect the complexity of biohybrid and tissue-engineered products. Adaptive approval mechanisms, conditional access programs, and an emphasis on post-market surveillance are becoming more common, which influences how companies plan evidence generation and market entry. These transformative shifts create both opportunities and constraints, requiring organizations to adopt integrated strategies across R&D, regulatory, manufacturing, and clinical adoption functions.

Assessing the cascade effects of new United States tariff measures in 2025 on supply chains clinical access manufacturing economics and innovation pathways

The introduction of tariff measures announced by the United States in 2025 has introduced a new layer of complexity into the global value chain for artificial organs and bionics. Tariff-driven cost pressures affect raw materials, precision components, and finished subsystems, with downstream implications for device assembly, validation, and distribution. Manufacturers that rely on cross-border sourcing for critical components face decisions about supplier diversification, reshoring, or strategic stockpiling to mitigate exposure and maintain production continuity.

Clinical providers and procurement teams are feeling the effects through increased acquisition complexity and a heightened focus on total cost of ownership. As a result, purchasing decisions are trending toward solutions that demonstrate clear operational efficiencies, reduced lifecycle maintenance, and predictable serviceability. For developers, tariff-related constraints have increased the importance of modular architectures and component standardization, allowing for substitution where geopolitical constraints make a particular supply line unreliable.

In addition to immediate cost impacts, tariffs influence strategic investment in regional manufacturing capacity. Companies are evaluating capital allocation to ensure proximity to key markets while balancing scale advantages. Regulatory and reimbursement considerations interact with these commercial choices, since localized production can facilitate regulatory submissions and native-language clinical support. Overall, tariffs have accelerated a strategic recalibration across sourcing, manufacturing footprint, and value proposition design, encouraging more resilient and regionally diversified business models.

Decoding product technology application and end-user segmentation to reveal nuanced demand drivers clinical touchpoints and investment focal areas

A granular understanding of product-level segmentation is indispensable for elevating strategic clarity and prioritizing development efforts. The product mix spans artificial hearts, kidneys, livers, bionic limbs, and neural prostheses, and each product class carries distinct clinical workflows, regulatory pathways, and manufacturing complexities. Within artificial hearts, differentiation between total artificial heart systems and ventricular assist devices highlights divergent use cases, implantation complexity, and downstream care models. Similarly, artificial kidneys split between hemodialysis and peritoneal dialysis devices, which differ in patient self-management requirements and infrastructure dependencies. Artificial liver technologies bifurcate into bioartificial liver support and extracorporeal liver assist devices, each representing different levels of biological integration and short-term versus sustained support paradigms. Bionic limb development encompasses foot, hand, lower limb, and upper limb solutions, with variation in sensor fidelity, actuation mechanics, and training demands. Neural prosthesis offerings include cochlear implants, deep brain stimulators, and retinal implants, each interfacing with specialized neurological pathways and necessitating distinct clinical expertise for optimization.

Technology segmentation further clarifies strategic trade-offs. Bioartificial organs integrate living cells and scaffolds to emulate physiology more closely, whereas mechanical organs emphasize durable, engineered systems and well-characterized failure modes. Tissue-engineered organs occupy a middle ground, focusing on regenerative approaches that aim to restore native function over time. These technological distinctions influence regulatory evidence requirements, supply-chain composition, and long-term maintenance obligations.

Application-focused segmentation-spanning cardiovascular, hepatic, neurological, orthopedic, and renal indications-reveals differing clinical adoption curves and health-system priorities. For example, cardiovascular solutions often require tightly coordinated surgical programs and intensive perioperative care, while renal and hepatic support devices can intersect with chronic disease management pathways. End-user segmentation into ambulatory surgical centers, homecare environments, hospitals, and specialty clinics underscores how channel dynamics affect product design. Devices intended for hospitals prioritize robustness and integration with complex clinical workflows, while homecare solutions emphasize ease of use, remote monitoring, and simplified maintenance. Synthesizing insights across product, technology, application, and end-user lenses uncovers where investment in usability, supply-chain resiliency, and evidence generation will yield the greatest strategic return.

Regional dynamics and strategic positioning across the Americas Europe Middle East & Africa and Asia-Pacific shaping clinical adoption and manufacturing footprints

Regional context materially shapes strategic choices for developers, manufacturers, and health systems seeking to deploy artificial organ and bionics solutions. The Americas present a dynamic mix of advanced clinical infrastructure, mature reimbursement pathways in certain jurisdictions, and concentrated capital markets that reward demonstrable clinical outcomes and commercial traction. This environment supports early adoption of high-acuity interventions and encourages partnerships that can scale surgical programs and post-market evidence collection. Europe Middle East & Africa features heterogenous regulatory regimes and payer landscapes, with several regions emphasizing centralized procurement and clinical-network validation, which can favor collaborative deployment strategies and multi-center evidence generation. Health systems in this region often place a premium on interoperability with established clinical workflows and regional centers of excellence that can function as adoption hubs. Asia-Pacific offers a combination of rapid clinical adoption in select markets, significant manufacturing capacity, and a growing emphasis on localized innovation. Markets across the region differ in regulatory stringency and reimbursement design, yet collectively they present substantial opportunities for scalable manufacturing and cost-optimized device iterations.

Interregional dynamics also influence supply-chain design and investment decisions. Companies weighing manufacturing locations versus proximity to large patient populations must consider regulatory harmonization efforts, intellectual property considerations, and the potential for regional public-private partnerships that accelerate clinical trials and adoption. Cross-border collaboration models, such as licensing agreements and localized co-development efforts, are becoming increasingly attractive as firms seek to balance the advantages of global scale with the need for market-specific adaptations. Ultimately, successful regional strategies will be those that align clinical evidence generation, manufacturing footprint, and commercial engagement with the distinct healthcare delivery models that characterize each territory.

Competitive landscape intelligence emphasizing strategic collaborations vertical integration IP trends and commercialization tactics among leading stakeholders

Competitive patterns within the artificial organ and bionics arena are defined by a combination of technological differentiation, strategic partnerships, and execution capabilities across clinical validation and manufacturing. Leading players are those that align strong engineering platforms with clinical domain expertise, enabling faster translational progress and credible long-term support commitments. Intellectual property portfolios that protect core sensing, actuation, and biointegration technologies create durable advantages, particularly when combined with know-how in regulatory pathways and large-scale manufacturing processes. Equally important are go-to-market strategies that embed training, service networks, and data ecosystems to ensure that devices deliver consistent outcomes across diverse care settings.

Mergers, acquisitions, and strategic alliances continue to be significant levers for capability aggregation, allowing organizations to fill gaps in biologics expertise, electronics miniaturization, or global distribution. Companies investing in vertically integrated models can capture margin and quality control benefits, but they must also manage the capital intensity of such investments and the operational complexity of running hybrid biological-electromechanical production lines. In contrast, firms that specialize in platform technologies or components may adopt ecosystem playbooks, prioritizing interoperability and third-party partnerships to accelerate market penetration. Across all models, the most successful organizations are those that clearly articulate patient-centered value propositions, demonstrate reproducible clinical benefits, and maintain supply-chain transparency to satisfy both regulators and healthcare purchasers.

Actionable strategic priorities for industry leaders to accelerate commercialization mitigate geopolitical risk and optimize clinical and manufacturing pathways

Industry leaders must act deliberately to navigate the intersecting clinical, regulatory, and commercial challenges that define the advanced organ and bionics market. First, prioritize evidence strategies that marry randomized trial data with real-world performance metrics and remote monitoring insights, thereby creating a compelling narrative for payers and providers about long-term value. Simultaneously, invest in modular product architectures that facilitate component substitution and local assembly, reducing vulnerability to tariff shocks and component scarcity while preserving clinical functionality. Engaging early with regulatory agencies to pursue adaptive approval pathways and to design post-market surveillance protocols can accelerate patient access while ensuring safety and iterative improvement.

Strategic partnerships should be formed across the value chain, including alliances with contract manufacturers experienced in biologics and precision electronics, collaborations with health systems for clinical pathway design, and data partnerships that enable longitudinal outcome tracking. Companies should also integrate lifecycle service models that address training, remote support, and consumable supply to enhance adherence and clinical outcomes. From a geographic perspective, build a manufacturing and distribution footprint that balances proximity to major clinical markets with the efficiencies of scale, and consider co-development models that localize key capabilities. Finally, foster an organizational culture that combines clinical empathy with engineering rigor and regulatory foresight, ensuring that cross-functional teams can rapidly iterate on product improvements in response to real-world feedback.

Rigorous mixed-method research design detailing primary interviews secondary validation expert panels and triangulation approaches used in the analysis

The research underpinning this analysis employed a mixed-method approach designed to ensure robust triangulation of qualitative and quantitative inputs. Primary research included structured interviews with clinicians, hospital procurement leaders, manufacturing executives, and regulatory specialists to capture first-hand perspectives on clinical workflows, adoption barriers, and supply-chain realities. These conversations were complemented by expert roundtables that facilitated cross-disciplinary exchange and enabled validation of emergent themes. Secondary research incorporated publicly available regulatory guidance, peer-reviewed clinical literature, and corporate disclosures to contextualize primary findings and to map technology trajectories.

Data synthesis used thematic analysis to identify recurring patterns across interviews and literature, followed by comparative cross-case evaluation to highlight differential strategies across product classes and regions. Key assumptions and methodological choices were documented and subjected to internal peer review to reduce bias. Where appropriate, scenario analysis was applied to explore the implications of supply-chain disruptions, regulatory policy shifts, and clinical adoption accelerants. Finally, findings were validated through follow-up discussions with select stakeholders to ensure the analysis accurately reflected operational realities and strategic trade-offs encountered by organizations actively engaged in the field.

Synthesis of strategic implications underscoring resilience priorities partnership opportunities and pathways to scale advanced artificial organ and bionics solutions

The cumulative analysis points to a sector at a strategic crossroads where technological promise meets operational and commercial complexity. Progress in biomaterials, miniaturized electronics, and regenerative techniques has created a credible pathway toward more durable and physiologically integrated solutions. However, realizing that promise requires deliberate attention to regulatory strategy, manufacturing scale-up, and evidence generation that resonates with payers and providers. Geopolitical dynamics, including tariff actions and supply-chain unpredictability, add urgency to decisions around footprint localization and supplier diversity. At the same time, region-specific clinical practices and reimbursement frameworks necessitate adaptive commercialization approaches rather than one-size-fits-all models.

For organizations that align technical innovation with pragmatic execution-investing in modular designs, forging strategic partnerships, and building resilient supply chains-the coming period offers substantive opportunities to establish durable clinical and commercial positions. Those that underestimate the operational demands or fail to generate compelling clinical evidence may face elongated adoption cycles and constrained commercialization pathways. In short, the future will favor actors who can integrate scientific excellence with disciplined product development, clear clinical value articulation, and an organizational capability to respond rapidly to changing policy and market conditions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Organ & Bionics Market, by Product

  • 8.1. Artificial Heart
    • 8.1.1. Total Artificial Heart
    • 8.1.2. Ventricular Assist Device
  • 8.2. Artificial Kidney
    • 8.2.1. Hemodialysis Device
    • 8.2.2. Peritoneal Dialysis Device
  • 8.3. Artificial Liver
    • 8.3.1. Bioartificial Liver Support
    • 8.3.2. Extracorporeal Liver Assist Device
  • 8.4. Bionic Limb
    • 8.4.1. Foot
    • 8.4.2. Hand
    • 8.4.3. Lower Limb
    • 8.4.4. Upper Limb
  • 8.5. Neural Prosthesis
    • 8.5.1. Cochlear Implant
    • 8.5.2. Deep Brain Stimulator
    • 8.5.3. Retinal Implant

9. Artificial Organ & Bionics Market, by Technology

  • 9.1. Bioartificial Organs
  • 9.2. Mechanical Organs
  • 9.3. Tissue Engineering Organs

10. Artificial Organ & Bionics Market, by Application

  • 10.1. Cardiovascular
  • 10.2. Hepatic
  • 10.3. Neurological
  • 10.4. Orthopedic
  • 10.5. Renal

11. Artificial Organ & Bionics Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Homecare
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Artificial Organ & Bionics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Artificial Organ & Bionics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Artificial Organ & Bionics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Artificial Organ & Bionics Market

16. China Artificial Organ & Bionics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Abiomed Inc
  • 17.7. Asahi Kasei Medical Co Ltd
  • 17.8. B Braun SE
  • 17.9. Baxter International Inc
  • 17.10. Berlin Heart GmbH
  • 17.11. BiVACOR Pty Ltd
  • 17.12. Boston Scientific Corporation
  • 17.13. CARMAT SA
  • 17.14. Cochlear Ltd
  • 17.15. CYBERDYNE Inc
  • 17.16. Edwards Lifesciences Corporation
  • 17.17. Ekso Bionics Holdings Inc
  • 17.18. Fresenius Medical Care AG
  • 17.19. Getinge AB
  • 17.20. Jarvik Heart Inc
  • 17.21. LifeNet Health Inc
  • 17.22. MED-EL
  • 17.23. Medtronic plc
  • 17.24. Open Bionics
  • 17.25. Orthofix International NV
  • 17.26. Ottobock
  • 17.27. SynCardia Systems
  • 17.28. Terumo Corporation
  • 17.29. Zimmer Biomet Holdings Inc
  • 17.30. Ossur

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HEMODIALYSIS DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HEMODIALYSIS DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HEMODIALYSIS DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PERITONEAL DIALYSIS DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PERITONEAL DIALYSIS DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PERITONEAL DIALYSIS DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIOARTIFICIAL LIVER SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIOARTIFICIAL LIVER SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIOARTIFICIAL LIVER SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY EXTRACORPOREAL LIVER ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY EXTRACORPOREAL LIVER ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY EXTRACORPOREAL LIVER ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY FOOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY FOOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY FOOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY LOWER LIMB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY LOWER LIMB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY LOWER LIMB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY UPPER LIMB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY UPPER LIMB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY UPPER LIMB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COCHLEAR IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COCHLEAR IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COCHLEAR IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY DEEP BRAIN STIMULATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY DEEP BRAIN STIMULATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY DEEP BRAIN STIMULATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY RETINAL IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY RETINAL IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY RETINAL IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIOARTIFICIAL ORGANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIOARTIFICIAL ORGANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIOARTIFICIAL ORGANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY MECHANICAL ORGANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY MECHANICAL ORGANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY MECHANICAL ORGANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TISSUE ENGINEERING ORGANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TISSUE ENGINEERING ORGANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TISSUE ENGINEERING ORGANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HEPATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HEPATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HEPATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY RENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY RENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL HEART, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY ARTIFICIAL LIVER, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY BIONIC LIMB, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY NEURAL PROSTHESIS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ARTIFICIAL ORGAN & BIONICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)